New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
07:31 EDTACRXAcelRx announces top-line data from Phase 3 study of Sufentanil NanoTab
AcelRx Pharmaceuticals announced top-line data from its previously announced open-label, active-comparator study of its lead product candidate, the Sufentanil NanoTab PCA System. Top-line results of the Phase 3 clinical trial demonstrate that the Sufentanil NanoTab PCA System was non-inferior to intravenous patient-controlled analgesia with morphine for the primary endpoint of Patient Global Assessment of method of pain control over the 48-hour study period as determined by the combined percentage of patients with PGA ratings of "good" or "excellent".
News For ACRX From The Last 14 Days
Check below for free stories on ACRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 18, 2014
09:00 EDTACRXAcelRx attractive ahead of Zalviso PDUFA, says Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use